INTERSTITIAL FLUID OSMOTIC PRESSURE MEASURING DEVICE SYSTEM AND METHOD
20200196917 ยท 2020-06-25
Assignee
Inventors
Cpc classification
A61B5/0004
HUMAN NECESSITIES
H04L67/12
ELECTRICITY
A61B5/14532
HUMAN NECESSITIES
A61B5/6867
HUMAN NECESSITIES
A61B5/1473
HUMAN NECESSITIES
International classification
A61B5/145
HUMAN NECESSITIES
A61B5/00
HUMAN NECESSITIES
A61B5/1473
HUMAN NECESSITIES
Abstract
An interstitial fluid glucose measuring device, system and method, the device including first and second cavities, both configured to be in fluid communication with interstitial fluid outside the cavities, the first and second pressure sensors being configured to sense the pressure in the first and second cavities, respectively. The first cavity includes an active solution and is defined in part by a first glucose porous membrane interfacing on one side of the interior of the first cavity and on the other side configured to interface with the interstitial body fluid. The active solution includes a lectin and a polysaccharide.
Claims
1. An interstitial fluid glucose measuring device comprising first and second cavities, both configured to be in fluid communication with interstitial fluid outside the cavities, wherein a first and a second pressure sensor are configured to sense a pressure in said first and second cavities, respectively, wherein the first cavity comprises an active solution and is defined in part by a first glucose porous membrane interfacing on one side of the interior of said first cavity and on the other side configured to interface with the interstitial body fluid, and wherein the active solution comprises a lectin and a polysaccharide.
2. The interstitial fluid glucose measuring device of claim 1, wherein a lectin to polysaccharide molar ratio is from 3:1 to 1:1.
3. The interstitial fluid glucose measuring device of claim 1, wherein the lectin is Concanavalin A and the polysaccharide is dextran.
4. The interstitial fluid glucose measuring device of claim 1, wherein the first and second cavities comprise similar buffer solutions.
5. The interstitial fluid glucose measuring device of claim 1, wherein the pore diameter of the first glucose porous membrane is between 2 and 10 nm.
6. The interstitial fluid glucose measuring device of claim 1, wherein the second cavity is defined in part by a second glucose porous membrane interfacing on one side the interior of said second cavity and on the other side configured to interface with the interstitial body fluid.
7. The interstitial fluid glucose measuring device of claim 6, wherein the first and second cavities and the first and second membranes, respectively, are identical.
8. The interstitial fluid glucose measuring device of claim 6, wherein the first pressure sensor is arranged opposite the first glucose porous membrane in the first cavity.
9. The interstitial fluid glucose measuring device of claim 6, wherein the first and second pressure sensors are absolute pressure sensors.
10. The interstitial fluid glucose measuring device of claim 9, further comprising a vacuum chamber as a reference for at least one of the first and second pressure sensors.
11. A method for measuring an interstitial fluid glucose level, comprising: allowing glucose from an interstitial fluid to pass through a first glucose porous membrane and into a first chamber comprising an active solution comprising a lectin and a polysaccharide; passing glucose from the interstitial fluid into a second chamber; measuring a pressure in a first and a second chamber using a first and a second pressure sensor, respectively; and calculating a glucose concentration dependent value from the difference between an output signal from the first and second absolute pressure sensors.
12. The method for measuring an interstitial fluid glucose level of claim 11, wherein a lectin to polysaccharide molar ratio is from 3:1 to 1:1.
13. The method for measuring an interstitial fluid glucose level of claim 12, wherein the lectin is Concanavalin A (ConA) and the polysaccharide is dextran.
14. The method for measuring an interstitial fluid glucose level of claim 11, wherein the first glucose porous membrane has a pore diameter between 2 and 10 nm.
15. The method for measuring an interstitial fluid glucose level of claim 11, wherein passing glucose from the interstitial fluid into a second chamber further comprises passing the glucose from the interstitial fluid through a second glucose porous membrane.
16. The method for measuring an interstitial fluid glucose level of claim 11, further comprising calculating a glucose concentration output value from the glucose concentration dependent value, based on a predetermined calibration scheme.
17. The method for measuring an interstitial fluid glucose level of claim 11, wherein measuring pressure in the first and second chamber, comprises measuring the pressure with the first and second absolute pressure sensors, respectively.
18. A glucose measuring system comprising an interstitial fluid glucose measuring device according to claim 1 10 and an external device, wherein the interstitial fluid glucose measuring device and the external device both have wireless interfaces, and are arranged to communicate wirelessly.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
EMBODIMENTS OF THE INVENTION
[0044] In the following description, various examples and embodiments of the invention are set forth in order to provide the skilled person with a more thorough understanding of the invention. The specific details described in the context of the various embodiments and with reference to the attached drawings are not intended to be construed as limitations. Rather, the scope of the invention is defined in the appended claims.
[0045] In the following the structural elements of the invention will be explained, while aspects of the active composition used in the first cavity will be explained thereafter. The combination of the two results in a positive synergetic effect as explained in the short summary section.
[0046] The structural elements of the invention will be explained with reference to an embodiment of the invention illustrated in the cross section of
Sensor Structure
[0047] The interstitial fluid osmotic pressure measuring device (1) comprises a first cavity (10) and a second cavity (20), both configured for being in fluid communication with interstitial fluid outside the cavities.
[0048] Further, the device comprises first and second pressure sensors (12, 22), are configured for sensing the pressure in said first and second cavities (10, 20), respectively.
[0049] The first cavity (10) comprises an active solution that is a composition comprising a lectin and a polysaccharide.
[0050] A first glucose porous membrane (11) allowing glucose molecules to flow through the membrane in both directions, but preventing the larger lectin and polysaccharide molecules to leave the first cavity (10), defines a part of the cavity. In the Fig. the membrane is in the form of a flat lid on top of the cavity, but other shapes and implementations are possible as long as a fluid connection between the interstitial fluid and the cavity for exist for glucose molecules. As explained above, the osmotic pressure inside the cavities will increase when the number of glucose molecules entering the cavity increases.
[0051] The device (1) further comprises first and second pressure sensors (12, 22), arranged to sense a first and a second pressure (P1, P2) in the first and second cavity (10, 20), respectively. The pressure sensor output will reflect the change in osmolality in the two chambers. The pressure sensors will typically be pressure transducers able to sense a mechanical deflection as a result of varying pressure.
[0052] In an embodiment, the first pressure sensor (12) is arranged opposite the first glucose porous membrane (11) in the first cavity (10) and/or the second pressure sensor (22) is arranged opposite the second glucose porous membrane (21) in the second cavity (10).
[0053] In this embodiment the device (1) comprises a vacuum chamber (40), with a fluid having a pressure level below ambient pressure, and the first and second pressure sensors (12, 22), are arranged to sense the first and the second pressure (P1, P2) with respect to the pressure in the vacuum chamber (40). The pressure measurements are therefore absolute pressure measurements with a fixed reference.
[0054] The pressure sensors (12, 22) in
[0055] In an embodiment, the first and/or second pressure sensors (12, 22) are therefore absolute pressure sensors.
[0056] In an embodiment the interstitial fluid glucose measuring device (1) comprises a vacuum chamber (40) being a reference for at least one of the first and second pressure sensors (12, 22).
[0057] Absolute pressure measurements use the absolute zero, or vacuum, as the reference point; as opposed to gauge measurements used in prior art where ambient pressure is used as the reference. In
[0058] The pressure sensors comprises in an embodiment an array of embedded micro electro mechanical (MEMS) switches which closes in turn as the membrane and the support structure is moving relative to each other in response to changing trans-membrane pressure gradients. The MEMS switches would act as a mechanical analogue to digital converter transforming a pressure change directly into a bit stream, or alternatively a series of discrete voltages or resistance changes depending on the applied bias circuitry. Such sensors can be found as off-the-shelf products, based on e.g., a piezo resistive or a capacitive principle. The resolution of the system is in this embodiment limited by the number of switches incorporated into each sensing element, and the number of sensing elements used. However, nano-technology makes it possibility to enhance the resolution of such MEMS arrangements and at the same time reduce size.
[0059] The output signal from the pressure sensors, will be sent to an electronic circuit module (not shown), typically implemented on a printed circuit board (PCB) (60).
[0060] In an embodiment the electronic the interstitial fluid glucose measuring device (1) comprises a processing unit arranged for calculating a glucose concentration dependent value from the difference between output signals from the first and second absolute pressure sensors (12, 22). For many purposes the glucose concentration dependent value is sufficient for further processing of the signal, either in the device itself or in an external device.
[0061] In the case where the absolute or real glucose concentration value is needed, a glucose concentration output value is calculated, in a further embodiment, from the glucose concentration dependent value, based on a predetermined calibration scheme.
[0062] The device (1) may also comprise a radio transmitter wherein the differential signal, or the or absolute glucose concentration value signal is transformed to make it suitable for wireless transmission, and sent to an external receiver unit, according to prior art radio technology. Both the coding (protocol) and the frequency is chosen to provide data integrity, security and low power consumption.
[0063] The energy for the electronic circuit and the transmitter can either be supplied internally from a battery, or by for instance magnetic induction.
[0064] The device (1) comprises in this embodiment a support structure (3) defining the cavities (10, 20, 40). The illustration is meant to illustrate the principle of the device according to the invention, and the support structure (3) may have many equivalent implementations. E.g., the first and second chambers (10, 20) may belong to two separate mechanical structures, two vacuum chambers can be used instead of one, the membranes may be mechanically separated etc. The actual implementation will depend on design choices, such as the use of off-the shelf components and the technology used for micromachining. In this case, the support structure (3) is surface micro machined on top of the substrate (3a).
[0065] The output from the pressure sensors are wire bond and accessible from the PCB (60). Depending on the type and number of pressure sensor elements (14, 24), there may be a number of such wire bindings, where only one from each of the first and second chamber (10, 20) has been illustrated.
[0066] All components above may be installed in a housing (2) with perforations (2a) allowing the interstitial fluid to be in direct contact with the first and second membranes (11, 21). An O-ring (12b) between the housing and the membrane is also shown.
[0067] In an embodiment the pressure sensors (12, 22) are variable capacitors.
[0068] In the illustration in
[0069]
[0070]
[0071] As will be explained more thoroughly later, detection of glucose is based on the competition between glucose (220) and a polysaccharide to bind to a receptor, the lectin. Lectin (211) and polysaccharide (212) are present in the reagent chamber in an active fluid and enclosed in the first cavity (10) by the nanoporous membrane (210) which is glucose permeable. At low glucose concentration, as can be seen in
[0072] In addition to the first cavity and the first pressure sensor, a second cavity and a second pressure sensor is also shown. The second pressure sensor will measure all pressure changes that are not related to changes in glucose concentration, such as hydrostatic pressure changes. The signal value from the second pressure sensor can then be used as a basis for determining the changes related to glucose concertation in the first pressure sensor, since the first sensor is also affected by additional pressure changes related to e.g. hydrostatic pressure.
[0073] The support structure (3) and the MEMS components can be manufactured by known Silicon micromachining techniques, where microscopic mechanical parts can be fashioned out of a silicon substrate or on a silicon substrate. Both micromachining and surface micromachining, including silicon wafer bonding, can be used.
[0074]
[0075] The sensing structure (12a, 22a) is in this example attached to a rigid base substrate of silicon, glass, ceramic or polymer being part of the support structure (3), and to a spacer (3a) made from one of the materials used in the support structure (3).
[0076] In some examples of embodiments the base substrate 5, spacer 6, is made from the same piece of material.
[0077] In the example of embodiment depicted in
[0078] In an example of embodiment of the present invention, an internally located battery or RF induced power from an externally located source powers the Wheatstone bridge. In another example of embodiment of the present invention, a pulsating signal is used to power the Wheatstone bridge, for example from the RF source powering the Wheatstone bridge. The measurements signals from the sensor can be processed in a phase lock (lock in) amplifier that will further cancel noise components and other surrounding RF signals from the measurement signals as known to a person skilled in the art.
[0079] The output voltages Vo+ and Vo can in an embodiment be transmitted wirelessly to an externally located processing unit providing further processing of the measurements, as known to a person skilled in the art.
[0080] In another embodiment the output voltages Vo+ and Vo are converted, in an Analog to Digital converter to a digital signal, e.g. a 24 bit digital signal before being transmitted over a wireless protocol, as known by a person skilled in the art,
[0081] In another example of embodiment as depicted in
[0082] The switches can be manufactured using traditional MEMS fabrication technologies in which alternating electrically conducting layers or adjacent components are brought in or out of contact as the membrane moves back and forth. Nanofabrication technologies have facilitate the integration of high density switching arrays to a great extent. The sensor device according to the present invention will in its basic configuration measure absolute osmotic pressures.
[0083] Glucose molecules in open chain form have a diameter of about 1.5 nm. The glucose permeable membranes should therefore preferably have pore diameter larger than 1.5 nm.
[0084] In an embodiment the pore diameter is between 2 and 10 nm.
[0085] Further, the membrane can be an asymmetric membrane with an active layer and a base layer, where the diameter indicated above is for the active layer and the pore diameter of the base layer is larger than for the active layer.
[0086] Preferably the base layer is mounted towards the first cavity (10).
[0087] Since the membrane is intended for implantation in a body, the material should be non-toxic and biocompatible. In an embodiment the first glucose permeable membrane is a ceramic membrane made from monolithic nanoporous anodic aluminum oxide (AAO), as available to the person skilled in the art.
[0088] In an embodiment, a semi-permeable membrane is enclosing a part of the second cavity (20). This is preferably a second glucose porous membrane (11) interfacing on one side the interior of said second cavity (20) and on the other side arranged for interfacing the interstitial body fluid. However, since the second cavity does not contain any active fluid, no osmotic pressure change will result from a change in the glucose concentration.
[0089] When the two cavities both have glucose permeable membranes, large and small hydrostatic pressure changes as well as small changes in pressure caused by other factors, such as other osmotic contributions, not due to the active solution, that would otherwise appear as noise or measurement errors, can be filtered out by subtracting one signal from the other.
[0090] In an embodiment, related to the embodiment above, the first and second cavities (10, 20) and the first and second membranes (12, 22) are identical, respectively. In this situation, no calibration or normalization of the sensor output signals from the first and second sensors is necessary to obtain a filtered output value representing the glucose level.
[0091] In an embodiment the invention is a glucose measuring system comprising an interstitial fluid glucose measuring device (1) according to any of the embodiments above and an external device (not illustrated), wherein the interstitial fluid glucose measuring device (1) and the external device both have wireless interfaces, and are arranged to communicate wirelessly.
[0092] In an embodiment the system comprises a processor arranged for calculating a glucose concentration dependent value from the difference between output signals from the first and second absolute pressure sensors (12, 22). The processor may be arranged in the measuring device or in the external device. The glucose concentration dependent is a function of the glucose concentration
[0093] In a related embodiment an absolute glucose concentration output value is calculated from the glucose concentration dependent value, based on a predetermined calibration scheme.
[0094] In an embodiment the modulated wireless signal between the glucose measuring device (1) and the external device is digital. This makes the design more immune to interference and scalable.
Active Solution
[0095] The sensing principle of an implantable glucose sensor relies on osmotic pressure variations between a reagent chamber and the solution, see illustrations in
[0096] The osmotic pressure of an ideal solution of low concentration can be approximated using the Morse equation:
=iMRT
where i is the dimensionless Van't Hoff factor, M is the molarity, R the gas constant and T the temperature of the chamber.
[0097]
[0098] The inventors found that lowering the viscosity of the composition would consequently reduce the asymmetry and response time of the sensor. In order to diminish the viscosity of the active fluid, the following parameters were explored while varying the glucose concentration in the solutions: [0099] Molecular weight of the dextran (10 kDa, 40 kDa or 70 kDa) [0100] Ratio of ConA to dextran [0101] Initial concentration of ConA.
[0102]
[0103] Lowering the ConA concentration and more specifically, the ConA to dextran concentrations ratio, was expected to decrease the number of intermolecular bonds between dextran and ConA, thus lowering the viscosity of the system. To investigate this effect, the ConA to dextran was reduced from 6:1 to 3:1, using the following concentrations ConA 1.5 mM, dextran 0.5 mM and glucose range 2 to 30 mM.
[0104]
[0105] Decreasing the molar ratio of ConA to dextran to 1:1 was shown to improve the amplitude of the response of the sensor. Lowering the number of intermolecular bonds between ConA and dextran also lowered the viscosity. The inventors chose to test a slightly higher concentration of dextran (1 mM instead of 0.5 mM) since it was also shown to improve the amplitude of the response and the sensitivity of the sensor. An active fluid with a ConA and dextran concentrations of 1 mM showed an amplitude of response approximately three times larger than the amplitude of response of the baseline active fluid described above.
[0106] By keeping the molar concentrations of dextran and ConA equal (at 1 mM), the viscosity was further decreased by an order of magnitude when compared to 3:1 molar ratio of ConA to dextran, see
[0107] For characterizations, each solution was stirred during 24 hours before viscosity measurements. A Brookfield DV-II+Pro viscometer was used for all measurements. The viscometer drives a spindle through a calibrated spring which is immersed in the active fluid. The viscous drag of the fluid against the spindle is measured by the spring deflection, which is measured with a rotary transducer. The measurement range is determined by the rotational speed of the spindle, the size and shape of the spindle, the container where the spindle is rotating in, and the full scale torque of the calibrated spring. The viscosity appears in units of centipoise (shown cP). One centipoise is equal to 1 mPa.Math.s in USI.
[0108] To control the temperature (T) at which the measurements were done, the viscometer was equipped with a water bath which can be set at the chosen T. All the viscosity measurements were performed at 37 C., with a 5 min. waiting period to ensure stabilisation of the temperature in the active fluid.
[0109] Based on viscosity measurements and simulation results, the inventors found clear trends in term of sensitivities and kinetics of the sensor can be established: [0110] A 1 to 1 molar concentration ratio of ConA to dextran was advantageous with respect to the sensitivities in term of osmotic pressure in the range of glucose concentration [0;30] mM. [0111] A 1 to 1 molar concentration ratio of ConA to dextran was advantageous with respect to fast kinetics and the least asymmetrical response to glucose variations since the viscosity of the active fluid varied very little with the glucose concentration. [0112] At 1 to 1 molar concentration ratio of ConA to dextran, a high ConA concentration (=dextran concentration) gave better sensitivity. However, it was also likely to increase the viscosity of the system, in turn increasing the time response of the sensor. [0113] Experimental studies of the viscosities of different active fluids were performed. These showed a rapid drop (of 3 orders of magnitude) as the concentration of ConA was decreased from 3 mM (based on monomer concentration) to 1 mM. Changes in the concentration of dextran also influenced the viscosity but to a lesser extent. In contrast the molecular weight of the dextran (10 kDa, 40 kDa, 70 kDa) could change the viscosity by orders of magnitude, see
[0117] The inventors performed a number of experiments to test the response of different active fluids, e.g.: [0118] 1.0 mM ConA, 1.0 mM dextran 40 kDa and 1.0 mM ConA, 1.0 mM dextran 70 kDa. [0119] 1.5 mM ConA, 1.5 mM dextran 40 kDa and 1.5 mM ConA, 1.5 mM dextran 70 kDa.
Test of Active Fluids Based on 1.5 mM ConA, 1.5 mM Dextran 40 kDa
[0120] Experiments were carried out by cycling the contents of the sample chamber in a macrocell between 2 mM glucose (in a solution containing 100 mM Trizma B buffer, 150 mM NaCl, 10 mM MgCl2 and 10 mM CaCl2)) and 30 mM glucose in the same solution. At each change of glucose concentration, the solution was removed by hand using a pipette, taking great care not to touch the nanoporous (NP) membrane but bringing the pipette tip as close as possible to the bottom of the sample chamber. The solution was then replaced by the new chosen solution, which was agitated by pumping the pipette. The solution was removed and replaced by fresh solution another two times. Temperature was 21 C.
[0121] Following this procedure, a reproducible signal was obtained. A change from 2 mM glucose to 30 mM glucose resulted in a large spike down in the measured pressure, followed by a slow rise to a new pressure that was approximately 10 mbar higher than the original value. A change from 30 mM glucose to 2 mM glucose gave a large spike up in measured pressure followed by a slow drift downwards (see
[0122] These two features can be understood when we consider the time course of the events taking place in sample chamber and active fluid chamber, as described below.
1) Starting at low glucose concentration, to begin with, all small solutes are present in equal concentrations on both sides of the NP membrane. Most of the ConA and dextran inside the active fluid chamber is bound together, giving a small overpressure inside the chamber.
2) Glucose is added outside the NP membrane. The concentration of solutes is briefly higher outside the membrane than inside. There is a brief underpressure inside the chamber.
3) The glucose diffuses through the membrane. Small solutes are present in equal concentrations on both sides of the NP membrane. ConA and dextran dissociate and the measured pressure increases to finally give an overpressure inside the chamber.
[0123] Thus the observed spike is not an artifact, but shows the process of equilibration of the glucose concentration on the two sides of the membrane.
[0124] Results of the study on the active fluids also shows that the present active fluid compositions could be studied for 3 months with no perceptible loss of sensitivity, i.e. long term stability.
[0125] The following section describes different embodiments of the active fluid solution being part of the invention. These embodiments can individually be combined with all the embodiments of the structural elements of the sensor described above.
[0126] In a first aspect the present invention provides an active fluid composition for use as an active fluid in a continuous glucose sensor comprising a carbohydrate-binding molecule, the carbohydrate-binding molecule being a lectin; a lectin-binding molecule, the lectin-binding molecule being a polysaccharide; at least one chloride salt of a divalent metal ion, and optionally glucose, wherein the said lectin to said polysaccharide molar ratio may be from 3:1 to 1:1.
[0127] In a first embodiment the lectin to polysaccharide molar ratio in the said composition is from 2:1 to 1:1. In a second embodiment the lectin to polysaccharide molar ratio in the said composition is 3:1, 2:1 or 1:1.
[0128] In a third embodiment the polysaccharide in the said composition may be dextran or other polysaccharide, having a molecular weight 10-100 kDa, e.g. 10-70 kDa. The dextran may have a molecular weight of 10 kDa, 40 kDa or 70 kDa.
[0129] In a fourth embodiment the concentration of said lectin in the said composition may be 0.2-5 mM, 0.5-3 mM or more specific 1-1.5 mM.
[0130] In a fifth embodiment the lectin in the said composition is Concanavalin A (ConA).
[0131] In a sixth embodiment the concentration of the polysaccharide in the said composition is 0.2-5 mM, 0.5-3 mM or more specific 1-1.5 mM.
[0132] In a seventh embodiment the concentration of ConA in the composition is 0.2-5 mM, more specific 0.5-3 mM, 1-1.5 mM, 1.5 mM or 1 mM based on the monomer concentration, and the concentration of dextran is 0.2-5 mM, more specific 0.5-3 mM, 1-1.5 mM, 1.5 mM or 1 mM. In an eight embodiment the ConA concentration in the composition is 1 mM based on the monomer concentration, and the dextran concentration is 1 mM. In a ninth embodiment the said ConA concentration is 1.5 mM based on the monomer concentration, and the dextran concentration is 1.5 mM.
[0133] In a tenth embodiment the composition, according to any of the above embodiments, may further comprise an aqueous buffer solution with pH 7.0-7.8. The buffer may be a Tris buffer or HEPES.
[0134] In a specific embodiment according to the tenth embodiment, the aqueous buffer solution contains 10-120 mM, for instance 100 mM, of a Tris buffer. In another specific embodiment according to the tenth embodiment the aqueous buffer solution in said composition contains 1-40 mM, or 1-20 mM, of HEPES buffer. The aqueous buffer solution, according to the tenth embodiment, may have a pH 7.2-7.6, for instance 7.35-7.5 or 7.4-7.5.
[0135] Verification of pH in the buffer solution may be performed at room temperature or 37 C. using a reference pH meter. Other temperatures may also be utilized depending on the intended use of the composition.
[0136] In an eleventh embodiment of the said composition, according to any of the above embodiments, the at least one chloride salt of a divalent metal ion is chosen from MgCl2, CaCl2) and MnCl2. In a specific embodiment of the eleventh embodiment, the at least one chloride salt of a divalent metal ion, or a combination thereof is dissolved in the said aqueous buffer solution giving concentrations 1-10 mM MgCl2, 1-10 mM CaCl2) and 1-10 mM MnCl2. The aqueous solution may also comprise NaCl giving an isotonic solution.
[0137] In a specific embodiment according to the eleventh embodiment, the said aqueous buffer solution comprises at least one of 10 mM MgCl2, 10 mM CaCl2) and 10 mM MnCl2 or a combination thereof and 150 mM NaCl, and optionally 20-40 mM glucose. In another specific embodiment according to the eleventh embodiment, the aqueous buffer solution contains 10 mM MgCl2, 10 mM CaCl2), 150 mM NaCl, and 30 mM glucose. The presence of glucose minimizes ConA-dextran binding, keeping the viscosity of the solution low and making handling easier.
[0138] In the composition to the present invention, according to any of the above embodiments, the water used in the aqueous buffer solution is reverse osmosis water, deionized water or distilled water.
[0139] In a specific embodiment a composition according to present invention has the following composition [0140] 1.0 mM or 1.5 mM ConA based on the monomer concentration, [0141] 1.0 mM or 1.5 mM dextran 40 or dextran 70, [0142] Tris buffer 100 mM, pH 7.4-7.5, [0143] 10 mM MgCl2, 10 mM CaCl2) and 150 mM NaCl, [0144] 30 mM glucose
wherein the said lectin to said polysaccharide molar ratio is 1:1.
In an embodiment, that can be related to any of the embodiment structural elements of the device, the first and second cavities (12, 22) comprise similar buffer solutions.
[0145] In the exemplary embodiments, various features and details are shown in combination. The fact that several features are described with respect to a particular example should not be construed as implying that those features by necessity have to be included together in all embodiments of the invention. Conversely, features that are described with reference to different embodiments should not be construed as mutually exclusive. As those with skill in the art will readily understand, embodiments that incorporate any subset of features described herein and that are not expressly interdependent have been contemplated by the inventor and are part of the intended disclosure. However, explicit description of all such embodiments would not contribute to the understanding of the principles of the invention, and consequently some permutations of features have been omitted for the sake of simplicity or brevity.